The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: -0.50 (-3.08%)
Spread: 0.50 (3.226%)
Open: 16.25
High: 16.25
Low: 15.70
Prev. Close: 16.25
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Finsbury Food's Annual Revenue Set To Fall

Wed, 15th Jul 2020 11:47

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

----------

Finsbury Food Group PLC - bakery and food service firm - Expects annual revenue to be GBP306.3 million, down from GBP315.3 million, due to declines in UK Bakery and Overseas division. First half revenue grew by 4.7% to GBP159.4 million, but second half was affected by Covid-19, with revenue falling by 9.8% to GBP146.9 million

----------

Open Orphan PLC - pharmaceutical services - Signs option to acquire CHIMagents Ltd for nominal sum. CHIMagents recently established to assist in design and manufacture of challenge agents for use in challenge studies. Open Orphan has three months to exercise the option.

----------

Air Partner PLC - aviation services - Security business Redline appointed to develop and deliver security management system for ISS Australia & New Zealand. ISS is a facility services provider, which provides security, screening and facility services across airports and ports. Trading remains ahead of budget with underlying pretax profit of GBP10 million in the first five months of 2020.

----------

Cambridge Cognition Holdings PLC - brain health firm based in Cambridge - Collaborates with 4YouandMe and Center for International Emergency Medical Services to investigate use of wearables and mobile phones to measure stress recovery in health works in the US caring for Covid-19 positive patients. Virtual study to take place over six months with up to 500 participants.

----------

Destiny Pharma PLC - Brighton-based biotechnology firm - Notes launch of USD1 billion AMR Action Fund to provide financial resources and technical support to help biotechnology companies bring novel anti-infective drugs to patients.

----------

Kodal Minerals PLC - mineral exploration and development - Signs USD1.5 million unsecured convertible loan agreement with Riverfort Global Opportunities PCC and YAII PN Ltd, which will allow for the continued development of its flagship Bougouni lithium project in Mali, and its gold projects in Mali and the Ivory Coast.

----------

Woodbois Ltd - Africa-focused timber producer - Raises GBP13.1 million through placing, retail offer and subscription of 655.0 million shares at a price of 2.0 pence per share, which will go towards expanding its production capacity and margins in Gabon, as well as grow its trading activities worldwide. Intends to pay dividend at end of 2021 financial year.

----------

Premier African Minerals Ltd - southern Africa-focused miner - Ministry of Industry, Commerce & Enterprise Development confirms that National Indigenisation & Economic Development Fund-appointed directors at RHA Tungsten Pvt Ltd can continue to act in their capacity. This removes one obstruction to finding a mutually acceptable solution to RHA's funding and equity dilemma.

----------

Caspian Sunrise PLC - oil & gas exploration - All Kazakh regulatory and shareholder approvals have been received, and relevant paperwork sent to UAE to complete the required re-registration of ownership of the Caspian Explorer, allowing for the acquisition of the asset.

----------

Allergy Therapeutics PLC - Sussex-based biotechnology firm - Expects earnings to be ahead of market expectations For year ended June 30. Revenue set to be GBP78.2 million, up 6% from GBP73.7 million. To repay all UK furlough monies claimed back to the government. Grass MATA MPL clinical programme expected to start next month as planned.

----------

AFC Energy PLC - hydrogen power generation technology developer - Forms collaboration with electric international rally series Extreme E to supply hydrogen fuelled, off-grid power for electric SUV racing due to start in early 2021.

----------

Carr's Group PLC - agriculture and engineering firm - For 19-week period ended July 11, trading remains in line with management expectations for financial year ending August 29. Agriculture division ahead of expectations, but Engineering unit affected by temporary interruptions to nuclear and defence projects. To pay interim dividend of 2.25p per share on October 2.

----------

BATM Advanced Communications Ltd - Israel-based data and telecommunications company - Develops three new test kits for Covid-19. Serologic test upgraded to measure quantity of antibodies in blood instead of just presence or absence. Antigen test upgraded to detect spike S gene to allow for diagnosis of Covid-19 in people with low viral loads. New molecular diagnostics test to identify specific respiratory virus. Sales and production to begin at start of fourth quarter of 2020.

----------

Mission Group PLC - creative agency - Expects revenue for first half of 2020 to be GBP29 million, down from GBP39 million the year before. Anticipates pretax loss of GBP2.2 million in interim period versus profit of GBP3.4 million. However, for 2020 as a whole, expects to deliver a profitable performance but at lower levels than 2019.

----------

Alpha FX Group PLC - currency risk management and payments - For first half of 2020, revenue increased by 16% to GBP18.0 million from GBP15.6 million, as average revenue per client rose with net increase of 28 clients to 671. Continues to invest in back office headcount and graphic expansion despite challenging environment.

----------

Bezant Resources PLC - operator of Kalengwa copper-gold project in Zambia and Hope copper-gold project in Namibia - Due diligence on Hope project progressing as planned, with combined mineral resource of 10.2 million tonnes at 1.9% copper and 0.3 grams per tonne of gold. From metallurgical test work, excellent recoveries made of 96% copper and 84% gold to a 28% copper grade.

----------

Portmeirion Group PLC - homewares manufacturer and distributor based in Stoke-on-Trent - Sales for six months to June to be down 8% at GBP32 million from GBP34.9 million. Like-for-like sales down 20%, excluding sales from Nambe division acquired in July 2019. Expects to report low single million pound pretax loss compared to profit of GBP500,000.

----------

Real Estate Investors PLC - Midlands-focused real estate investment trust - Rent collection for quarter to the end of June rises to 90.2% from 81% reported on June 15. Meanwhile rent collection for quarter ending September is 82% so far. Expects to pay 0.5 pence per share dividend on July 24.

----------

SEC Newgate Spa - communications, advocacy and research - Launches TRUE, an AI-powered platform to run new-to-market semantic and reputation assessments. Initially function in Italian, but can work five other languages, including English, French, German and Spanish. English version expected to be available in fourth quarter of 2020.

----------

Hydrogen Group PLC - recruitment firm - For the first six months of 2020, net fee income at GBP11.7 million, down from GBP15.3 million, as Covid-19 pandemic impacted client demand from Asia Pacific in January, which spread to its EMEA and US businesses over time.

----------

Arcontech Group PLC - market data software firm - Profit for year to the end of June set to be in line with market expectations, while net cash as at June 30 is GBP5.0 million, up from GBP4.1 million.

----------

GCP Asset Backed Income Fund Ltd - Asset backed loans investor - Net asset value per share as at June 30 was 100.83 pence. Will continue to keep in place discount rate movements on loans made to different investments due to continued uncertainty from Covid-19 pandemic.

----------

By Dayo Laniyan; dayolaniyan@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.